Clinical Trial Update: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pralatrexate and oxaliplatin in unresectable or metastatic esophageal, stomach, or gastroesophageal junction cancer has been c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction
• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Esophageal Undifferentiated Carcinoma
• Gastric Adenocarcinoma
• Gastric Cancer
• Gastric Carcinoma
• Gastric Squamous Cell Carcinoma
• Stage Iiib Esophageal Adenocarcinoma
• Stage Iiib Esophageal Squamous Cell Carcinoma
• Stage Iiib Gastric Cancer
• Stage Iiic Esophageal Adenocarcinoma
• Stage Iiic Esophageal Squamous Cell Carcinoma
• Stage Iiic Gastric Cancer
• Undifferentiated Gastric Carcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-13